R-CHOP-21 Remains the Standard for Diffuse Large B-Cell Lymphoma

No benefit was observed for R-CHOP administered every 14 days versus every 21 days for newly diagnosed DLBCL.

Increasing the dose intensity of chemotherapy for newly diagnosed diffuse large B-cell lymphoma (DLBCL) has been proposed as a means to improve survival and cure rates.

To test this approach, investigators in the U.K. conducted a phase III, multicenter, prospective, open-label, randomized trial involving 1080 patients with DLBCL (93% with stage II–IV disease; 7% with bulky IA or IB disease). Patients received either standard-dose R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone) administered every 21 days for eight cycles or R-CHOP administered every 14 days for six cycles followed by two cycles of rituximab. Filgrastim was administered per protocol to all R-CHOP-14 patients and to R-CHOP-21 patients at the…

Reviewing Author

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee